<DOC>
	<DOCNO>NCT00870194</DOCNO>
	<brief_summary>The purpose study determine whether cease sitagliptin switch exenatide metformin non-inferior add exenatide sitagliptin metformin , patient type 2 diabetes experience inadequate glycemic control combination sitagliptin metformin .</brief_summary>
	<brief_title>A Comparison Adding Exenatide With Switching Exenatide Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Present type 2 diabetes Patients treat stable dose follow least 3 month prior screen : 100 mg/day sitagliptin ≥1500 mg/day metformin , maximum tolerate dose ( extended release immediaterelease ) . Have inadequate glycemic control evidence HbA1c 7.1 % 9 % , inclusive . Have body mass index ( BMI ) ≥20 kg/m2 &lt; 45 kg/m2 Are currently enrol , discontinue within last 30 day ( long , local guideline require ) , clinical trial involve offlabel use investigational drug device , concurrently enrol type medical research judge scientifically medically compatible study . Have previously complete withdrawn study study investigate exenatide . Have know allergy hypersensitivity exenatide , sitagliptin excipients contain exenatide sitagliptin . Used drug weight loss ( example , orlistat , sibutramine , phenylpropanolamine , similar overthecounter medication ) within 1 month screening . Are currently treat follow excluded medication : Thiazolidinediones ( TZD ) within 3 month screen . Sulfonylurea ( SU ) within 3 month screen . Dipeptidyl peptidase4 [ DPP4 ] inhibitor , exception sitagliptin , within 3 month screen . Meglitinide derivative ( example , repaglinide nateglinide ) within 3 month screen . Alphaglucosidase inhibitor ( example , miglitol acarbose ) within 3 month screen . Exogenous insulin within 3 month prior screen . Drugs directly affect gastrointestinal motility , include , limited : metoclopramide , cisapride , chronic macrolide antibiotic . Systemic corticosteroid ( exclude topical inhale preparation ) oral , intravenous ( IV ) , intramuscular ( IM ) route use regularly ( longer 1 month ) use within 1 month immediately prior screening . Any oral antidiabetic ( OAD ) agent , sitagliptin metformin , within 3 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>Byetta</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>Januvia</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>